Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00736541 · ClinicalTrials.gov registry record · NA
N-acetylcysteine in Liver Transplantation
A NA study of End Stage Liver Failure, sponsored by Ibtesam Hilmi.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT00736541 is a NA study of End Stage Liver Failure that has completed, run by Ibtesam Hilmi. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00736541, a NA study of End Stage Liver Failure, has completed, sponsored by Ibtesam Hilmi.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
N-acetylcysteine (NAC) is used to treat Tylenol toxicity. NAC is a rich source of the sulfhydryl group (SH) which is important for replenishing the body's glutathione stores. Glutathione acts as a free radical scavenger, to decrease the damage that would be caused by those toxic radicals. Patients who undergo orthotopic liver transplantation (OLT) have a high incidence of post-operative renal dysfunction. The most common etiology of post-operative renal dysfunction is related to high levels of toxic free radicals. Free radicals may contribute to primary liver graft failure or delayed liver graft function. Specific Aims \& Objectives: The primary objective of this study is to evaluate the efficacy of NAC in improving liver graft performance and lowering the incidence of post-operative renal dysfunction. The secondary objectives are to investigate the effect of NAC on endogenous glutathione body stores and its effect on FK506 induced toxicity.
Conditions Studied
Interventions
- DRUG N-acetylcysteine
Study Locations (1)
Pennsylvania
- Unversity of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2004-07 |
| Est. Completion | 2008-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00736541
The ClinicalTrials.gov registry entry for NCT00736541 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ibtesam Hilmi, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with End Stage Liver Failure appearing as the primary indexed condition, and to 1 intervention - of which N-acetylcysteine is the first listed.
NCT00736541 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00736541 about?
NCT00736541 is a clinical study titled "N-acetylcysteine in Liver Transplantation". N-acetylcysteine (NAC) is used to treat Tylenol toxicity. NAC is a rich source of the sulfhydryl group (SH) which is important for replenishing the body's glutathione stores. Glutathione acts as a free radical scavenger, to decrease the damage that would be caused by those toxic radicals. Patients w...
What is the current status of trial NCT00736541?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2004-07. Estimated completion is 2008-01.
What conditions does trial NCT00736541 study?
This clinical trial studies the following conditions: End Stage Liver Failure.
What interventions are being tested in trial NCT00736541?
The interventions under investigation include: N-acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT00736541?
This trial is sponsored by Ibtesam Hilmi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00736541 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.